US Broker Ratings

AxoGen, Inc. (AXGN) Stock Analysis: Exploring a 37% Potential Upside in the Healthcare Sector

Investors with an eye on the healthcare sector might find AxoGen, Inc. (NASDAQ: AXGN) an intriguing candidate for their portfolios. Specializing in medical devices, this Florida-based company has carved a..

Cel-Sci Corporation (CVM) Stock Analysis: A Potential 1,902% Upside in Biotech Innovation

Cel-Sci Corporation (NYSE American: CVM) has caught the attention of investors with its staggering potential upside of 1,902.39%, as suggested by recent analyst ratings. This clinical-stage biotechnology company, headquartered in..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unlocking a 41% Upside in the Biotech Sector

Theravance Biopharma, Inc. (NASDAQ: TBPH) is capturing investor interest with its notable potential upside of 41.44%, a compelling figure for those looking to delve into the dynamic biotechnology sector. With..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating the Biotech Terrain Amidst Challenging Metrics

Ginkgo Bioworks Holdings, Inc. (NASDAQ: DNA), a prominent player in the biotechnology sector, is drawing considerable attention from investors due to its innovative approach to cell programming and its potential..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Uncovering an 86.75% Potential Upside in Biotech

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is making waves in the biotechnology sector with its focus on developing breakthrough treatments for severe autoimmune and inflammatory diseases. With a market capitalization of..

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: A Potential 156.76% Upside with Innovative Cancer Therapies

Syndax Pharmaceuticals, Inc. (SNDX) has recently caught the attention of investors with a compelling potential upside of 156.76%, as indicated by its average target price of $37.69 against a current..

Collegium Pharmaceutical, Inc. (COLL): Investor Outlook with a Promising 25% Upside

For investors eyeing opportunities in the healthcare sector, Collegium Pharmaceutical, Inc. (NASDAQ: COLL) presents an intriguing proposition. Specializing in the development and commercialization of pain management medications, this U.S.-based specialty..

Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem with 150% Potential Upside

Savara, Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, is garnering attention from investors with its promising focus on rare respiratory diseases. With a market capitalization of $712.09 million, this U.S.-based..

Cross Country Healthcare, Inc. (CCRN) Stock Analysis: Assessing the 45.50% Potential Upside

For investors eyeing opportunities within the healthcare sector, Cross Country Healthcare, Inc. (NASDAQ: CCRN) presents a compelling case with its significant potential upside. Despite the current challenges reflected in its..

Precigen, Inc. (PGEN) Stock Analysis: Exploring a Biotech Powerhouse with 94% Upside Potential

Precigen, Inc. (NASDAQ: PGEN), a trailblazer in the biopharmaceutical sector, has captured investor attention with its advanced gene and cell therapy platforms targeting critical areas such as immuno-oncology, autoimmune disorders,..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Unveiling a 199% Upside Potential in the Biotech Sector

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is capturing the attention of investors with its significant upside potential in the biotech industry. This Watertown, Massachusetts-based company, with a market cap of approximately..

Weave Communications, Inc. (WEAV) Investor Outlook: Analyzing a 76.4% Potential Upside

Weave Communications, Inc. (NYSE: WEAV) may not yet be a household name, but its innovative approach to health information services is gaining traction among investors seeking growth opportunities in the..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Exploring a 61.91% Potential Upside

Praxis Precision Medicines, Inc (NASDAQ: PRAX), a Boston-based clinical-stage biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to treating central nervous system (CNS) disorders. With..

Bioventus Inc. (BVS) Stock Analysis: Unpacking a 110.73% Potential Upside

Investors with an eye on the healthcare sector might find Bioventus Inc. (NASDAQ: BVS) an intriguing prospect. The company, which specializes in medical devices aimed at pain relief and musculoskeletal..

InnovAge Holding Corp. (INNV) Stock Analysis: A Cautious Investor Outlook Amid Modest Growth

InnovAge Holding Corp. (NASDAQ: INNV) operates within the healthcare sector, specifically focusing on medical care facilities. The company is well-known for its Program of All-Inclusive Care for the Elderly (PACE),..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating Growth Amidst a 7.25% Potential Upside

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the healthcare sector, has carved out a niche in the diagnostics and research industry. With a market capitalization of $722.99 million,..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a 29.28% Potential Upside in the Biotech Sector

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to pioneering treatments for neurodegenerative and endocrine disorders. With a current market capitalization of $1.53..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Promising 403% Upside in the Biotechnology Sector

Anavex Life Sciences Corp. (NASDAQ: AVXL) stands as a compelling prospect in the biotechnology sector, with a market capitalization of $750.71 million. The company, headquartered in New York, is dedicated..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 37% Potential Upside Beckons Investors in a High-Stakes Biotech Play

Zenas BioPharma, Inc. (NASDAQ: ZBIO) stands as a compelling opportunity in the healthcare sector, particularly for investors with a penchant for high-growth biotech ventures. With a market capitalization of $1.18..

COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a Bold 150% Potential Upside in Biotech

COMPASS Pathways Plc (CMPS) emerges as a fascinating player in the healthcare sector, particularly in the medical care facilities industry. This UK-based biotechnology company is actively involved in pioneering mental..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds